The treatment landscape is evolving rapidly, with various competitive threats emerging. Notable competitors include Inventiva Pharma’s Lanifibranor (IVA337), Akero Therapeutics’ Efruxifermin, Sagimet Biosciences’ Denifanstat, 89bio’s Pegozafermin, Novo Nordisk’s WEGOVY (semaglutide)<\/b>, and others.<\/p>\n
In addition, several liver fibrosis drugs are currently being developed at various stages, including HU6<\/b> from Rivus Pharmaceuticals, LPCN 1144 <\/b>from Lipocine, MN-001<\/b> from MediciNova, Icosabutate<\/b> from NorthSea Therapeutics, Lixudebart (ALE.F02) <\/b>from Alentis Therapeutics, PHIN-214<\/b> from PharmaIN, and FXR314 <\/b>from Organovo.<\/p>\n
Competing liver fibrosis therapies in advanced clinical stages, including Inventiva’s lanifibranor and Akero Therapeutics’ efruxifermin<\/b>, pose direct competition. Lanifibranor, in particular, offers a differentiated pan-PPAR agonist approach, potentially competing with REZDIFFRA’s efficacy and safety profile.<\/p>\n
Discover which therapies are expected to grab major liver fibrosis market share @ Liver Fibrosis Market Report<\/a><\/b><\/p>\n Efruxifermin (EFX)<\/b>\u00a0is Akero Therapeutics’ primary candidate for MASH treatment. This Fc-FGF21 fusion protein is designed to replicate the natural activity of FGF21, a hormone that reduces cellular stress and helps regulate metabolism. EFX offers the convenience of once-weekly subcutaneous injections and is being developed for pre-cirrhotic MASH (F2-F3) and compensated cirrhosis due to MASH (F4). Early results suggest that EFX could potentially become a leading treatment for MASH if approved. In January 2025, Akero Therapeutics announced the completion of patient enrollment in the Phase III SYNCHRONY Real-World study for MASH or MASLD (F1-F4), with results expected in the first half of 2026.<\/p>\n Pegozafermin (BIO89-100)<\/b>\u00a0is a compound that activates the fibroblast growth factor 21 (FGF21) receptor, a hormone involved in glucose and lipid metabolism. It has shown promise as a therapeutic for MASH. In January 2025, the company emphasized its strong position for the year, with ongoing Phase III trials in MASH. It expects to release topline data from its first Phase III trial in late 2025. The company is also conducting two Phase III trials\u2014ENLIGHTEN-Fibrosis for non-cirrhotic MASH (F2-F3) patients and ENLIGHTEN-Cirrhosis for compensated cirrhotic MASH (F4) patients\u2014both of which are actively enrolling global patients.<\/p>\n BOS-580 (Efimosfermin Alfa)<\/b>\u00a0is a long-acting, once-monthly FGF21 analogue in development for MASH. This investigational fusion protein targets three FGF21 receptors for a balanced pharmacological effect. In November 2024, Boston Pharmaceuticals reported positive Phase II data for BOS-580 in F2\/F3 MASH at AASLD 2024. The treatment showed significant improvement in fibrosis (\u22651 stage) with no worsening of MASH after 24 weeks. Two-thirds of patients treated with BOS-580 achieved significant MASH resolution without worsening fibrosis, compared to placebo. The Phase II trial also showed reductions in liver injury markers, fibrosis, and improvements in metabolic health. BOS-580 has demonstrated low discontinuation rates in clinical trials, with gastrointestinal issues being the most common side effects. In June 2024, data presented at EASL Congress 2024 highlighted significant improvements in lipid profiles with BOS-580 treatment.<\/p>\n Denifanstat<\/b>, a selective fatty acid synthase (FASN) inhibitor, is advancing in Phase III trials for MASH, targeting De Novo Lipogenesis (DNL) to reduce palmitate production. In October 2024, Sagimet Biosciences concluded successful end-of-Phase II discussions with the US FDA, moving denifanstat into Phase III trials. The FASCINATE-3 trial focuses on non-cirrhotic MASH (F2\/F3), and FASCINIT examines patients with suspected or confirmed MASLD\/MASH. In February 2025, Sagimet announced lipidomic data from the Phase IIb FASCINATE-2 trial, focusing on triglycerides and LDL cholesterol in advanced fibrosis, which will be presented at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium. The US FDA granted denifanstat Breakthrough Therapy (BTD) and Fast Track Designation (FTD) for non-cirrhotic MASH with moderate to advanced fibrosis.<\/p>\n Survodutide<\/b>, a dual GLP-1\/glucagon receptor agonist, is also in Phase III development for MASH and fibrosis, targeting key metabolic pathways. In October 2024, Boehringer Ingelheim initiated the LIVERAGE trials, including LIVERAGE for MASH with fibrosis and LIVERAGE-Cirrhosis for MASH with cirrhosis. The US FDA granted Survodutide BTD for non-cirrhotic MASH with fibrosis, while the European Medicines Agency (EMA) included it in its Priority Medicines (PRIME) scheme for NASH. Boehringer Ingelheim and Zealand Pharma received US FDA support, highlighting Survodutide’s potential to address unmet needs in MASH treatment.<\/p>\n Discover more about drugs for liver fibrosis\u00a0in development @ Liver Fibrosis Clinical Trials<\/a><\/b><\/p>\n The anticipated launch of these emerging therapies for liver fibrosis\u00a0are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the liver fibrosis\u00a0treatment market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n DelveInsight estimates that the market size for liver fibrosis is expected to grow from USD 2.1 billion<\/b> in 2024, with a significant CAGR of ~24%<\/b> by 2034. This anticipated growth in the liver fibrosis market is driven by advancements in treatment options, greater healthcare access, and a rising prevalence of liver fibrosis, which together foster higher demand for innovative and effective therapies.<\/p>\n DelveInsight’s latest published market report, titled as Liver Fibrosis Market Insight, Epidemiology, and Market Forecast \u2013 2034<\/a><\/b>, <\/b>will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the liver fibrosis country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market’s underlying potential. The liver fibrosis market forecast report\u00a0proffers epidemiological analysis for the study period 2020\u20132034 in the 7MM segmented into:<\/p>\n Total Liver Fibrosis Diagnosed Prevalent Cases<\/p>\n<\/li>\n Liver Fibrosis Severity-specific Diagnosed Prevalent Cases<\/p>\n<\/li>\n Total Liver Fibrosis Diagnosed Prevalent Cases (\u2265F2 Stage) in MASH<\/p>\n<\/li>\n<\/ul>\n The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM liver fibrosis market. Highlights include:<\/p>\n 10-year Forecast<\/p>\n<\/li>\n 7MM Analysis<\/p>\n<\/li>\n Epidemiology-based Market Forecasting<\/p>\n<\/li>\n Historical and Forecasted Market Analysis upto 2034<\/p>\n<\/li>\n Emerging Drug Market Uptake<\/p>\n<\/li>\n Peak Sales Analysis<\/p>\n<\/li>\n Key Cross Competition Analysis<\/p>\n<\/li>\n Industry Expert’s Opinion<\/p>\n<\/li>\n Access and Reimbursement<\/p>\n<\/li>\n<\/ul>\n Download this liver fibrosis market forecast report to assess the epidemiology forecasts, understand the patient journeys, know KOLs’ opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the liver fibrosis treatment market. Also, stay abreast of the mitigating factors to improve your market position in the liver fibrosis therapeutic space.<\/p>\n Related Reports<\/b><\/p>\n Liver Fibrosis Pipeline<\/a><\/b><\/p>\n Liver Fibrosis Pipeline Insight \u2013 2025<\/b>\u00a0report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key\u00a0liver fibrosis companies, including Galmed Research and Development, Ltd, AstraZeneca, Galectin Therapeutics, Resolution Therapeutics, AdAlta, Novo Nordisk A\/S, Sagimet Biosciences Inc., Hepion Pharmaceuticals, Inc., Pliant Therapeutics, Inc., Inipharm, GAT Therapeutics, TiumBio, INVENT Pharmaceuticals, SFA Therapeutics, <\/b>among others.<\/p>\n Non-Alcoholic Fatty Liver Disease\u00a0Market<\/a><\/b><\/p>\n Non-Alcoholic Fatty Liver Disease<\/b>\u00a0Market Insight, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key NAFLD companies, including\u00a0MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc.<\/b>, <\/b>among others.<\/p>\n Metabolic Dysfunction-Associated Steatohepatitis\u00a0Market<\/a><\/b><\/p>\n Metabolic Dysfunction-Associated Steatohepatitis<\/b>\u00a0Market Insight, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key MASH companies, including\u00a0Inventiva Pharma, Novo Nordisk A\/S, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics, Lipocine, Viking Therapeutics, Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai), Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics<\/b>, <\/b>among others.<\/p>\n Nonalcoholic Steatohepatitis Pipeline<\/a><\/b><\/p>\n Nonalcoholic Steatohepatitis Pipeline Insight <\/b>\u2013 2025<\/b>\u00a0report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nonalcoholic steatohepatitis\u00a0companies, including\u00a0Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, <\/b>among others.<\/p>\n About\u00a0DelveInsight<\/b><\/p>\n DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve.<\/b><\/p>\n Contact Us \n
\n
<\/b>Shruti Thakur \u00a0
info@delveinsight.com<\/a> \u00a0
+14699457679<\/p>\n